The Centro Nacional de Investigaciones Oncológicas Carlos III (CNIO) has presented new imidazo[1,2-b]pyridazine-based tricyclic compounds acting as serine/threonine-protein kinase haspin (GSG2) inhibitors and reported to be useful for the treatment of cancer.